Eculizumab is approved by the FDA in patients for generalized MG who test positive for AchR antibodies. Approval was based on data from the REGAIN phase 3 trial that compared eculizumab with placebo. The primary efficacy endpoint for generalized MG was a comparison of the change from baseline between treatment groups according to Myasthenia Gravis-Activities of Daily Living (MG-ADL) total score at week 26. Treatment with eculizumab showed a statistically significant difference in the mean change from baseline to week 26 in MG-ADL total scores (-4.2 points vs -2.3 points). In the open-label extension phase, MG exacerbation rate was reduced by 75% compared with the previous year in patients taking eculizumab (P < .0001). Additional C5 inhibitors (eg, zilucoplan; RAISE phase 3 trial [NCT04115293]) are completing phase 3 trials that show similar encouraging results.
Learn more about other treatments for MG.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Mary L. Windle. Rapid Rx Quiz: Myasthenia Gravis Treatments - Medscape - Mar 15, 2022.
Comments